Volv Global helps detect diseases earlier using AI and biomarkers—cutting delays, lowering costs, and improving patient outcomes.
The idea that an AI system could detect a disease that appears nowhere in a patient's medical record sounds like…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Inflammatory Bowel Disease (IBD) management has evolved significantly with advanced therapies…
Introduction Advocacy plays a critical role in accelerating progress in rare diseases. As technology advances, collaboration between patient communities, researchers,…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction Earlier cancer detection remains one of the most powerful opportunities…
Finding the Patients We're Missing Rare diseases often remain undiagnosed for years, leaving patients without timely treatment and care. Despite…
In 2024, Sanofi – working in partnership with The BMJ – released the Rairity: Air Time For Rare Diseases podcast…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: COPD as a “Syndrome,” Not Just One Disease Chronic…
“The patient voice” is shorthand for patients’ and caregivers’ lived experience—captured in a way that can inform decisions. In other…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Introduction: A Silent Disease Becoming a Public Health Emergency Metabolic…
By Léon Van Wouwe, Clinical Innovation Director, Volv Global Early detection and personalised treatment in chronic lymphocytic leukaemia (CLL) remain…